QR kód

Simulating Costs of Intravenous Biosimilar Trastuzumab vs. Subcutaneous Reference Trastuzumab in Adjuvant HER2-Positive Breast Cancer: A Belgian Case Study

This study aimed to compare drug costs and healthcare costs of a 1 year adjuvant course with intravenous biosimilar trastuzumab vs. subcutaneous reference trastuzumab in HER2-positive breast cancer from the Belgian hospital perspective. Our simulation is based on the methodology used by Tjalma and c...

Celý popis

Uloženo v:
Hlavní autoři: Steven Simoens, Arnold G. Vulto, Pieter Dylst
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI AG 2021-05-01
Edice:Pharmaceuticals
Témata:
trastuzumab
biosimilar
intravenous
subcutaneous
HER2-positive breast cancer
drug costs
On-line přístup:https://www.mdpi.com/1424-8247/14/5/450
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky